Clinical Trial Update: A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma [Phase 2]

View source ↗

Summary

This is a Phase II study evaluating Rituximab in combination with CHOP for untreated Angioimmunoblastic T-cell lymphoma. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angioimmunoblastic T-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: Lymphoma Study Association | Conditions: Untreated T-cell Angioimmunoblastic Lymphoma | Phase 2 | Status: COMPLETED